SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-006980
Filing Date
2021-03-29
Accepted
2021-03-29 06:35:22
Documents
14
Period of Report
2021-03-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 36863
2 ex99-1.htm EX-99.1 104032
3 image_002.jpg GRAPHIC 4303
  Complete submission text file 0001493152-21-006980.txt   337311

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE mtnb-20210329.xsd EX-101.SCH 3211
5 XBRL LABEL FILE mtnb-20210329_lab.xml EX-101.LAB 34592
6 XBRL PRESENTATION FILE mtnb-20210329_pre.xml EX-101.PRE 22727
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3610
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-443-1860
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

IRS No.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 21779407
SIC: 2834 Pharmaceutical Preparations